Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Voyager Therapeutics' TRACER Capsids Show Encouraging Action In Animal Models

  • Voyager Therapeutics Inc (NASDAQ:VYGR) will present new preclinical data on a family of AAV9-derived TRACER capsids demonstrating cross-species central nervous system transduction at the American Society of Gene and Cell Therapy Annual Meeting.
  • Voyager's TRACER capsid discovery platform has identified a novel AAV9-derived capsid, VCAP-102, which demonstrated 50-fold better transduction in mice and 60-fold in non-human primates versus conventional AAV9 capsids after IV dosing.
  • Top variants from the capsid family exhibited increased blood-brain barrier (BBB)-penetrance across NHP species and mice.
  • Top variants showed preferential transduction of glial cells in mice.
  • The company is also scheduled to report updated results from preclinical gene therapy programs in GBA1, tauopathies, and SOD1 ALS. 
  • Multiple transgenes for the optimal expression of glucocerebrosidase 1 (GBA1), the gene encoding the lysosomal enzyme glucoslyceramidase, were characterized in vitro and in vivo mouse models.
  • Systemic dosing of a vectorized anti-tau antibody in mouse models reduced tau pathology. The antibody demonstrated robust efficacy in vectorized (vTau) and passive forms in a hippocampal seeding mouse model of Alzheimer's Disease.
  • AAV9-derived capsid containing superoxide dismutase 1a (SOD1)-targeting RNAi gene therapy improved motor performance and survival in a SOD1- amyotrophic lateral sclerosis mouse model.
  • Price Action: VYGR shares closed 3.96% lower at $6.30 on Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.